Use access key #2 to skip to page content.
$2.08 -0.11 (-5.02%)
10/7/2008 3:45 PM

Ligand Pharmaceuticals, Inc. (LGND)

CAPS Rating:
**

Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases.

View All Commentary (LGND)

Recs

1

Avatar Caedus (85.06) Submitted: 3/13/08 11:34 PM : Outperform Start Price: $4.01 LGND Score: -23.47

As patents for drugs begin to expire this year, many Japanese drug companies are looking to smaller U.S. based corporations to get a foothold on new products to offset their anticipated losses from the expiration of the patents. I foresee LGND being considered for acquisition, and the speculation will likely drive it's price up. They also have several upcoming releases which will spark their sales % upwards pending FDA approvals, and their current price is far below it's future potential.

Report this Post Replies: 0 | Reply

Featured Broker Partners